USPTO serial 79287747
VAXXAS
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Jul 13, 2021
- Examiner
- LEASER, ANDREW C
- Law office
- TMO LAW OFFICE 117
What this means
This registration is in, or will soon enter, a USPTO maintenance window. Missing a Section 8 or Section 9 filing can cancel the registration.
Need help with VAXXAS?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Renewal, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $1,544*
Plus Government fees of $1,950
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Sydney NSW, AU
Sydney NSW, AU
Sydney, NSW, AU
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Gregory M. Krakau
Gregory M. Krakau Krakau Law, P.C.100 Pine Street, Suite 1250San Francisco, CA 94111UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical, medicinal and therapeutic preparations for human and veterinary use for the treatment of infectious disease, allergies and oncology; vaccines; vaccine preparations; diagnostic preparations for medical or veterinary purposes; biological specimens, blood and plasma for human medical diagnostics and analysis; transdermal patches, bandages, poultices and medical dressings impregnated with vaccines; patches, bandages, poultices and medical dressings impregnated with vaccines; transdermal vaccine delivery system being patches for administering vaccines; pharmaceutical preparations for treating infectious disease, allergies and oncology contained in transdermal patches; skin patches for the transdermal delivery of pharmaceuticals for use in the treatment of infectious disease, allergies and oncology; transdermal patches for administering pharmaceuticals for use in the treatment of infectious disease, allergies and oncology and vaccines; intradermal patches for use in the medical treatment of infectious disease, allergies and oncology; intradermal vaccine delivery system being patches for administering vaccines; pharmaceutical preparations contained in intradermal patches for use in the medical treatment of infectious disease, allergies and oncology; skin patches for the intradermal delivery of pharmaceuticals for use in the treatment of infectious disease, allergies and oncology; intradermal patches for medical treatment for administering pharmaceuticals for use in the medical treatment of infectious disease, allergies and oncology and vaccines; micro-projection array patches for medical purposes impregnated with vaccines; structural parts and fittings for the aforesaid goods | ACTIVE | — |
| 010 | Surgical and medical apparatus and instruments, namely, vaccine and drug delivery microneedle array patches sold without medication; drug delivery devices and apparatus, namely, hermetically sealed applicators containing patches for applying vaccine sold without medication; drug delivery devices sold empty, namely, uncoated patches sold without medication; transdermal drug delivery devices and apparatus, namely, transdermal drug delivery patches sold without medication; intradermal drug delivery devices and apparatus, namely, intradermal drug delivery patches sold without medication; micro-projection drug delivery devices and apparatus, namely, drug delivery patches sold without medication; structural parts and fittings for the aforesaid goods | ACTIVE | — |
| 040 | Custom manufacturing services in the field of drug delivery patches; custom manufacture of medical devices, pharmaceuticals, diagnostic tests and testing kits; custom manufacture of micro-projection array patches; custom manufacture of drug delivery devices and apparatus; custom manufacture of transdermal drug delivery devices and apparatus; custom manufacture of intradermal drug delivery devices and apparatus; custom manufacture of micro-projection drug delivery devices and apparatus; advisory, consultancy and information services in relation to all of the aforesaid | ACTIVE | — |
| 042 | Research, design and development services in the field of medical apparatus and instruments; medical research, design and development services in the field of drug delivery devices; research and development in the pharmaceutical and biotechnology fields; research and development of vaccines and medicines; drug discovery; vaccine screening, namely, safety testing of vaccines; scientific and technological research services related to immunopharmaceuticals and vaccines; biological research, clinical research in the field of immunology, vaccines, and medical research; conducting clinical trials for others; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; chemical and biochemical analysis services; medical and scientific research; pharmaceutical research services; laboratory testing services in the field of vaccines, pharmaceuticals; laboratory research in the fields of biotechnology, microbiology, molecular biology, nanotechnology analytical chemistry, biochemistry, medicinal chemistry and drug development; technology services, namely, design and development of computer hardware; scientific research, clinical research, development, advisory and consultancy services in relation to antibody production; research and development services in the field of antibodies; antibody generation services being research and development services; diagnostic and research services and screening in the field of infectious disease, allergies and oncology for medical research purposes; diagnostic testing services in the field of medical apparatus and instruments; medical research services; advisory services relating to diagnostic testing of products for quality control and safety purposes; research and development of products; advisory, consultancy and information services in relation to all of the aforesaid | ACTIVE | — |
| 044 | Medical, medical clinic, and healthcare services relating to vaccines; medical and veterinary consultancy; medical testing for diagnostic or treatment purposes; advisory, consultancy and information services in relation to all of the aforesaid | ACTIVE | — |
| 045 | Legal services relating to the exploitation and licensing of intellectual property and technology; licensing of medical technology; legal services relating to the licensing of research and development of products; advisory, consultancy and information services in relation to all of the aforesaid | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Vaxxas Pty Ltd
- Other trademarks owned by Vaxxas Pty Ltd
- Other trademarks owned by Vaxxas Pty Ltd
- Other trademarks in Class 005
- Other trademarks in Class 010
- Other trademarks in Class 040
- Other trademarks in Class 042
- Other trademarks in Class 044
- Other trademarks in Class 045
- Similar marks named VAXXAS
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jul 13, 2026 | REM3 | COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED | — |
| Oct 10, 2023 | NURC | NOTICE OF UPDATED REGISTRATION CONFIRMATION EMAILED | — |
| Sep 5, 2023 | COC. | CORRECTION UNDER SECTION 7 - PROCESSED | — |
| Aug 30, 2023 | APRE | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | — |
| Mar 25, 2022 | APRE | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | — |
| Mar 25, 2022 | COC. | CORRECTION UNDER SECTION 7 - PROCESSED | — |
| Mar 24, 2022 | APRE | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | — |
| Nov 28, 2021 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Nov 9, 2021 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Nov 9, 2021 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Oct 31, 2021 | ES7R | TEAS SECTION 7 REQUEST RECEIVED | — |
| Oct 13, 2021 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Jul 13, 2021 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Apr 27, 2021 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Apr 27, 2021 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Apr 24, 2021 | GPNX | NOTIFICATION PROCESSED BY IB | — |
| Apr 7, 2021 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Apr 7, 2021 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| Apr 7, 2021 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Mar 23, 2021 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Mar 23, 2021 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Mar 22, 2021 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Mar 22, 2021 | ERFR | TEAS REQUEST FOR RECONSIDERATION RECEIVED | — |
| Mar 17, 2021 | GNFN | NOTIFICATION OF FINAL REFUSAL EMAILED | — |
| Mar 17, 2021 | GNFR | FINAL REFUSAL E-MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Mar 17, 2021 | CNFR | FINAL REFUSAL WRITTEN | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Feb 24, 2021 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Feb 23, 2021 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Feb 23, 2021 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Sep 10, 2020 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Sep 10, 2020 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Sep 10, 2020 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Aug 30, 2020 | RFNT | REFUSAL PROCESSED BY IB | — |
| Aug 20, 2020 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Aug 19, 2020 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Aug 19, 2020 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Aug 11, 2020 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Aug 11, 2020 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Jul 20, 2020 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Jul 19, 2020 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jul 11, 2020 | DOCK | ASSIGNED TO EXAMINER | — |
| Jun 24, 2020 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Jun 20, 2020 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jun 18, 2020 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |